CERO THERAPEUTICS HOLDINGS, INC.
Closed (deSPAC)Profile in progress
- What it is
- PBAX AND THE POTENTIAL BUSINESS COMBINATION
- What it’s doing now
- Merging with PHOENIX BIOTECH ACQUISITION CORP. (PBAX) — closed (despac).
- What you should know
- The deal carries a $30M minimum-cash condition — heavy redemptions can break it.
The business, per its filings
SEC primaryPBAX AND THE POTENTIAL BUSINESS COMBINATION. The Form S-4 and other documents in connection with the Potential Business Combination will be filed after you have made an investment decision one way or the other regarding any potential investment in Cero or PBAX. Because of this sequencing, when deciding whether to invest in Cero or PBAX, you should carefully consider the information made available to you, including this Presentation, through the date of your decision. If you sign a subscription agreement, you will be required to make certain representations relating to the foregoing. After the Proxy / Registration Statement is declared effective by the SEC, the definitive Proxy / Registration Statement will be mailed to PBAX’s stockholders as of a record date to be established for voting on the Potential Business Combination. Interested parties will also be able to obtain free copies of such documents filed with the SEC (once available) at the SEC’s website located at www.sec.gov, or security holders may direct a request to Phoenix Biotech Acquisition Corp., Attn: Secretary, 2201 Broadway, Suite 705, Oakland, CA.
What the company says about itself
Web research — not audited[WEB-INTEL 2026-08-26] 8 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Cero Therapeutics has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in March 2020." [https://startupintros.com/orgs/cero-therapeutics] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "CERo Therapeutics Completes First Tranche of $7 Million Financing to Support Clinical Development and Nasdaq Compliance" [https://www.quiverquant.com/news/CERo+Therapeutics+Completes+First+Tranche+of+%247+Million+Financing+to+Support+Clinical+Development+and+Nasdaq+Compliance] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "CERo Therapeutics secures $2.3 million of a planned $7 million financing to support clinical trials and Nasdaq compliance." [https://www.quiverquant.com/news/CERo+Therapeutics+Completes+First+Tranche+of+%247+Million+Financing+to+Support+Clinical+Development+and+Nasdaq+Compliance] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Announces Up to $8 Million Series D Financing" [https://finance.yahoo.com/news/cero-therapeutics-inc-announces-8-121500993.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "During Q1 2026, CERo raised about $1.96 million net, including proceeds from equity line of credit share purchases and two 10% convertible" [https://www.stocktitan.net/sec-filings/CERO/10-q-cero-therapeutics-holdings-inc-quarterly-earnings-report-7d453056740f.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "CERo Therapeutics has raised a total of $54.8M over 6 funding rounds: 1 Seed, 2 Early-Stage and 3 Post IPO rounds." [https://tracxn.com/d/companies/cero-therapeutics/__6IqrUYPFQTqN6UV2PNGsg0sf2f27VeO7qE1LUllujHk/funding-and-investors] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Upon closing of the transaction, anticipated to occur in the second half of 2023, the combined company will be named CERo Therapeutics Holdings," [https://www.businesswire.com/news/home/20230603005013/en/CERo-Therapeutics-Inc.-and-Phoenix-Biotech-Acquisition-Corp.-Announce-Merger-Agreement-to-Create-Public-Company-Advancing-the-Development-of-Next-Generation-Engineered-T-Cell-Therapeutics] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "(PBAX/W/U) & CERo Therapeutics Holdings, Inc. closed today, Wednesday, February 14, 2024." [https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2024-68]
Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
CERO THERAPEUTICS HOLDINGS, INC. is merging with PHOENIX BIOTECH ACQUISITION CORP. (PBAX) currently marked Closed (deSPAC).
| Headline equity value | — |
| Minimum cash to close | $30M |
Structure per SEC accession(s) 0001213900-23-058043. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is CERO THERAPEUTICS HOLDINGS, INC. going public?
CERO THERAPEUTICS HOLDINGS, INC. has an approved merger with the SPAC PHOENIX BIOTECH ACQUISITION CORP. (PBAX). Deal status: Closed (deSPAC).
Does CERO THERAPEUTICS HOLDINGS, INC. have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.